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Purpose. To update the American Society of Clinical
Oncology (ASCO)/College of American Pathologists (CAP)
guideline recommendations for human epidermal growth
factor receptor 2 (HER2) testing in breast cancer to
improve the accuracy of HER2 testing and its utility as a
predictive marker in invasive breast cancer.
Methods. ASCO/CAP convened an Update Committee
that included coauthors of the 2007 guideline to conduct a
systematic literature review and update recommendations
for optimal HER2 testing.
Results. The Update Committee identified criteria and
areas requiring clarification to improve the accuracy of
HER2 testing by immunohistochemistry (IHC) or in situ
hybridization (ISH). The guideline was reviewed and
approved by both organizations.
Recommendations. The Update Committee recommends
that HER2 status (HER2 negative or positive) be determined
in all patients with invasive (early stage or recurrence) breast
cancer on the basis of one or more HER2 test results
(negative, equivocal, or positive). Testing criteria define
HER2-positive status when (on observing within an area of
tumor that amounts to >10% of contiguous and homoge-
neous tumor cells) there is evidence of protein overexpres-
sion (IHC) or gene amplification (HER2 copy number or
HER2/CEP17 ratio by ISH based on counting at least 20 cells
within the area). If results are equivocal (revised criteria),
reflex testing should be performed using an alternative assay
(IHC or ISH). Repeat testing should be considered if results
seem discordant with other histopathologic findings. Labo-
ratories should demonstrate high concordance with a
validated HER2 test on a sufficiently large and representative
set of specimens. Testing must be performed in a laboratory
accredited by CAP or another accrediting entity. The Update
Committee urges providers and health systems to cooperate
to ensure the highest quality testing.
(Arch Pathol Lab Med. 2014;138:241–256; doi: 10.5858/
arpa.2013-0953-SA)
In 2007, a joint Expert Panel convened by the AmericanSociety of Clinical Oncology (ASCO) and the College of
American Pathologists (CAP) met to develop guidelines for
when and how to test for the human epidermal growth
factor receptor 2 (HER2) gene (also referred to as ERBB2),1,2
which is amplified and/or overexpressed in approximately
15% to 20% of primary breast cancers. Since then, minor
clarifications and updates to the ASCO/CAP HER2 testing
guideline have been issued.3–5 A detailed rationale for this
full 2013 update, as well as additional background infor-
mation, is available in Data Supplement 1.
In 2012, ASCO and CAP convened an Update Committee
to conduct a formal and comprehensive review of the peer-
reviewed literature published since 2006 and to revise the
guideline recommendations as appropriate. Since publica-
tion of the 2007 guideline, new diagnostic strategies, like
measures of HER2 amplification by bright-field in situ
hybridization, DNA expression by microarray, or mRNA
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The Bottom Line
ASCO Guideline Update
Recommendations for HER2 Testing in Breast Cancer: ASCO/CAP Guideline Update
Intervention
 Recommendations for HER2 testing in breast cancer
Target Audience
 Medical oncologists, pathologists, and surgeons
Key Recommendations for Oncologists
 Must request HER2 testing on every primary invasive breast cancer (and on metastatic site, if stage IV and if specimen available)
from a patient with breast cancer to guide decision to pursue HER2-targeted therapy. This should be especially considered for a
patient who previously tested HER2 negative in a primary tumor and presents with disease recurrence with clinical behavior
suggestive of HER2-positive or triple-negative disease.
 Should recommend HER2-targeted therapy if HER2 test result is positive, if there is no apparent histopathologic discordance with
HER2 testing (Tables 1 and 2), and if clinically appropriate. If the pathologist or oncologist observes an apparent histopathologic
discordance after HER2 testing, the need for additional HER2 testing should be discussed.
 Must delay decision to recommend HER2-targeted therapy if initial HER2 test result is equivocal. Reflex testing should be performed
on the same specimen using the alternative test if initial HER2 test result is equivocal or on an alternative specimen (Tables 1 and 2).
 Must not recommend HER2-targeted therapy if HER2 test result is negative and if there is no apparent histopathologic discordance
with HER2 testing (Tables 1 and 2). If the pathologist or oncologist observes an apparent histopathologic discordance after HER2
testing, the need for additional HER2 testing should be discussed.
 Should delay decision to recommend HER2-targeted therapy if HER2 status cannot be confirmed as positive or negative after
separate HER2 tests (HER2 test result or results equivocal). The oncologist should confer with the pathologist regarding the need for
additional HER2 testing on the same or another tumor specimen.
 If the HER2 test result is ultimately deemed to be equivocal, even after reflex testing with an alternative assay (ie, if neither test is
unequivocally positive), the oncologist may consider HER2-targeted therapy. The oncologist should also consider the feasibility of
testing another tumor specimen to attempt to definitely establish the tumor HER2 status and guide therapeutic decisions. A clinical
decision to ultimately consider HER2-targeted therapy in such cases should be individualized on the basis of patient status
(comorbidities, prognosis, and so on) and patient preferences after discussing available clinical evidence.
Key Recommendations for Pathologists
 Must ensure that at least one tumor sample from all patients with breast cancer (early-stage or metastatic disease) is tested for either
HER2 protein expression (IHC assay) or HER2 gene expression (ISH assay) using a validated HER2 test.
 In the United States, the ASCO/CAP Guideline Update Committee preferentially recommends the use of an assay that has received FDA
approval, although a CLIA-certified laboratory may choose instead to use a laboratory-developed test (LDT). In this case, the analytic
performance of the LDT must be prospectively validated in the same clinical laboratory that will perform it, and the test must have
documented analytic validity (CAP guidance document). Bright-field ISH assays must be initially validated by comparing them with an
FDA-approved FISH assay.
 Must report a HER2 test result as positive if: (a) IHC 3þ positive or (b) ISH positive using either a single-probe ISH or dual-probe
ISH (Table 1; Figs 1 to 3). This assumes that there is no apparent histopathologic discordance observed by the pathologist (Table 2).
 Must report a HER2 test result as equivocal and order reflex test on the same specimen (unless the pathologist has concerns about
the specimen) using the alternative test if: (a) IHC 2þ equivocal or (b) ISH equivocal using single-probe ISH or dual-probe ISH
(Table 1; Figs 1 to 3). This assumes that there is no apparent histopathologic discordance observed by the pathologist (Table 2). Note
that there are some rare breast cancers (eg, gland-forming tumors, micropapillary carcinomas) that show IHC 1þ staining that is
intense but incomplete (basolateral or U shaped) and that are found to be HER2 amplified. The pathologist should consider also
reporting these specimens equivocal and request reflex testing using the alternative test.
 Must report a HER2 test result as negative if a single test (or all tests) performed on a tumor specimen show: (a) IHC 1þ negative or
IHC 0 negative or (b) ISH negative using single-probe ISH or dual-probe ISH (Table 1; Figs 1 to 3). This assumes that there is no
apparent histopathologic discordance observed by the pathologist (Table 2).
 Must report a HER2 test result as indeterminate if technical issues prevent one or both tests (IHC and ISH) performed on a tumor
specimen from being reported as positive, negative, or equivocal. This may occur if specimen handling was inadequate, if artifacts
(crush or edge artifacts) make interpretation difficult, or if the analytic testing failed. Another specimen should be requested for
testing, if possible, and a comment should be included in the pathology report documenting intended action.
 Must ensure that interpretation and reporting guidelines for HER2 testing are followed (Table 1; Data Supplements 7, 8, 9, and 10).
 Should interpret bright-field ISH on the basis of a comparison between patterns in normal breast and tumor cells, because artifactual
patterns may be seen that are difficult to interpret. If tumor cell pattern is neither normal nor clearly amplified, test should be
submitted for expert opinion.
 Should ensure that any specimen used for HER2 testing (cytologic specimens, needle biopsies, or resection specimens) begins the
fixation process quickly (time to fixative within 1 hour) and is fixed in 10% neutral buffered formalin for 6 to 72 hours and that
routine processing, as well as staining or probing, is performed according to standardized analytically validated protocols.
 Should ensure that the laboratory conforms to standards set for CAP accreditation or an equivalent accreditation authority, including
initial test validation, ongoing internal quality assurance, ongoing external proficiency testing, and routine periodic performance
monitoring.
 If an apparent histopathologic discordance is observed in any HER2 testing situation (Table 2), the pathologist should consider
ordering additional HER2 testing and conferring with the oncologist, and should document the decision-making process and results
in the pathology report. As part of the HER2 testing process, the pathologist may pursue additional HER2 testing without conferring
with the oncologist.
 Although categories of HER2 status by IHC or ISH can be created that are not covered by these definitions, in practice they are
uncommon and if encountered should be considered IHC equivocal or ISH equivocal.
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expression reverse-transcriptase polymerase chain reaction,
have been introduced into practice, and the Update
Committee felt these required evidence-based review. The
Update Committee wishes to re-emphasize that it is
important that any new test methodology, for the same
clinical use, be compared with a reference test that assays for
the same analyte and for which there are high levels of
evidence that use of the test leads to clinical benefit for the
patient (ie, clinical utility). It is the opinion of the Update
Committee that there is insufficient evidence to support use
of mRNA or DNA microarray assays to determine HER2
status in unselected patients (Data Supplement 2A).
Further experience with established HER2 assays also led
to the identification of unusual HER2 genotypic abnormal-
ities, like aneusomy of chromosome 17 (polysomy and
monosomy), colocalization of HER2 and CEP17 signals that
affect HER2/CEP17 ratio in dual-signal in situ hybridization
(ISH) assays, and genomic heterogeneity. Limited retro-
spective data on the clinical significance of these abnormal-
ities in completed prospective trials also guided the
discussions that were part of this guideline update.6–22
Some of these issues are discussed in Data Supplements
2B and 2C and in a separate review article by Hanna et al.23
During the deliberations, the Update Committee was
concerned about false-negative and false-positive HER2
assessments. For example, a false-negative test result could
lead to denial of trastuzumab treatment for a patient who
could benefit from it. False-positive results could lead to the
administration of potentially toxic, costly, and ineffective
adjuvant HER2-targeted therapy for 1 year.24–27 The Update
Committee considered mandatory testing of all HER2-
negative tests (Data Supplement 2D) and addressed also a
narrower set of scenarios that may on occasion be observed
with dual-signal ISH assays (Data Supplement 2E; Inter-
pretation Criteria If Using a Dual-Signal HER2 Assay and
Average HER2 Copy Number ,6 Signals Per Cell).
Trastuzumab had previously been shown to improve
progression-free survival and overall survival when com-
bined with chemotherapy in the metastatic setting.28 Since
2005, several of the first-generation adjuvant trials have
been updated and have confirmed the disease-free and
overall survival benefit offered by 1 year of trastuzumab
administered with or after adjuvant chemotherapy.29–31
Prospective randomized trials, first reported in abstract
form in late 2012, seem to suggest that 12 months is the
optimal duration of adjuvant trastuzumab therapy.
Other HER2-targeted drugs (eg, the kinase inhibitor
lapatinib,32 the antibody pertuzumab,33 and the antibody-
drug conjugate ado-trastuzumab emtansine [T-DM1]34 )
have been approved for the treatment of HER2-positive
metastatic breast cancer. At the same time, data show that
lapatinib (when added to paclitaxel)35 and pertuzumab (as a
single agent)36 offer no clinical benefit in patients with
HER2-negative metastatic disease. These new HER2-tar-
geted drugs are now being tested in the adjuvant setting,
including in studies evaluating their adjuvant role alone or
in dual-antibody regimens without concomitant or sequen-
tial chemotherapy. Compared with regimens already in use,
the newer agents are as or more expensive, and they may be
associated with other dose-limiting toxicities, such as skin
and GI tract toxicities with lapatinib and liver toxicities with
ado-trastuzumab emtansine.37
Therefore, the need for an updated ASCO/CAP guideline
on accurate HER2 testing to ensure that the right patient
receives the right treatment is now more critical than
ever.22,24–27,38 Since the publication of the 2007 HER2 testing
guideline, CAP has observed a remarkable uptake of
proficiency testing (Fig 4),5 with nearly 1,500 laboratories
currently participating. CAP has also observed fewer
laboratories experiencing deficiencies on laboratory inspec-
tion. Indirect evidence suggests that the performance of
laboratories that conduct HER2 testing in the United States
and elsewhere is improving.39–42 Available evidence and
experience since 2007 reinforce the importance of robust
validation of new assays by laboratories before clinical
implementation, as well as their ongoing monitoring, and
the value of various external quality assurance schemes
adopted in many countries.
METHODS
The HER2 testing Update Committee (Appendix Table A1,
online only at www.asco.org/guidelines/her2) met 3 times via
Webinars coordinated by its Steering Committee to review the data
published from January 2006 to January 2013 and to revise the
recommendations. Additional data were gathered from in-press
publications and personal correspondence with researchers to
address the issue of mandatory testing if a test result is 0 or 1þ.
Draft manuscripts were circulated by e-mail, and the Update
Committee approved the final manuscript. This guideline was
reviewed by external reviewers and approved by the ASCO Clinical
Practice Guideline Committee and relevant CAP entities.
Literature Search Strategy
The MEDLINE and the Cochrane Collaboration Library elec-
tronic databases were searched with the date parameters of January
2006 through January 2013 for articles in English. The MEDLINE
search terms are included in Data Supplement 3, and a summary of
the literature search results is provided in Data Supplement 4.
Inclusion and Exclusion Criteria
Articles were selected for inclusion in the systematic review of
the evidence if they met the following criteria: (1) the study
compared, prospectively or retrospectively, fluorescent ISH (FISH)
and immunohistochemistry (IHC) results or other tests; described
technical comparisons across various assay platforms; examined
potential testing algorithms for HER2 testing; or examined the
The Bottom Line (Continued)
Methods
 Systematic review and analysis of the medical literature were conducted by the 2013 Update Committee.
Additional Information
 The revised recommendations and a brief summary of the literature and analysis are provided in this article. Data Supplements
including clinical tools and resources can be found at http://www.asco.org/guidelines/her2 and at http://www.cap.org. Patient
information is available at http://www.cancer.net. ASCO and CAP believe that cancer clinical trials are vital to inform medical
decisions and improve cancer care, and that all patients should have the opportunity to participate.
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correlation of HER2 status in primary versus metastatic tumors
from the same patients; (2) the study population consisted of
patients with a diagnosis of invasive breast cancer; or (3) the
primary outcomes included the negative predictive value (NPV) or
positive predictive value (PPV) of ISH and IHC assays used to
determine HER2 status, alone and in combination; negative and
positive concordance across platforms; and accuracy in determining
HER2 status and benefit from anti-HER2 therapy and in
determining sensitivity and specificity of individual tests. Consid-
eration was given to studies that directly compared results across
assay platforms.
Studies were not limited to randomized controlled trials but also
included other study types, including cohort designs, case series,
evaluation studies, and comparative studies. The Update Committee
also reviewed other testing guidelines and proficiency strategies of
various US and international organizations, including unpublished
data. Letters, commentaries, and editorials were reviewed for any
new information. Case reports were excluded. The clinical questions
addressed in the update are available in Data Supplement 5.
This information was used to help the Update Committee
develop new algorithms (for pathologists and oncologists) for
testing, specify testing requirements and exclusions, and facilitate
the necessary quality assurance monitoring that will make HER2
testing less variable and ensure more analytic consistency between
laboratories. The term ratio, as used in the guideline recommen-
dations and algorithms, always applies to the HER2/CEP17 ratio,
which means the ratio of HER2 signals per cell (numerator) over
CEP17 signals per cell (denominator).
ASCO Guideline Disclaimer
The clinical practice guideline and other guidance published
herein are provided by ASCO to assist practitioners in clinical
decision making. The information herein should not be relied on as
being complete or accurate, nor should it be considered as inclusive
of all proper treatments or methods of care or as a statement of the
standard of care. With the rapid development of scientific
knowledge, new evidence may emerge between the time informa-
tion is developed and when it is published or read. The information
is not continually updated and may not reflect the most recent
evidence. The information addresses only the topics specifically
identified herein and is not applicable to other interventions,
diseases, or stages of diseases. This information does not mandate
any particular course of medical care. Furthermore, the information
is not intended to substitute for the independent professional
judgment of the treating physician, because the information does
not account for individual variation among patients. Recommen-
dations reflect high, moderate, or low confidence that the
recommendation reflects the net effect of a given course of action.
The use of terms like must, must not, should, and should not
indicate that a course of action is recommended or not
recommended for either most or many patients, but there is
latitude for the treating physician to select other courses of action in
individual cases. In all cases, the selected course of action should be
considered by the treating physician in the context of treating the
individual patient. Use of the information is voluntary. ASCO
provides this information on an as-is basis and makes no warranty,
express or implied, regarding the information. ASCO specifically
disclaims any warranties of merchantability or fitness for a
particular use or purpose. ASCO assumes no responsibility for
any injury or damage to persons or property arising out of or
related to any use of this information or for any errors or omissions.
CAP Guideline Disclaimer
Clinical practice guidelines reflect the best available evidence and
expert consensus supported in practice. They are intended to assist
physicians and patients in clinical decision making and to identify
questions and settings for further research. With the rapid flow of
scientific information, new evidence may emerge between the time
a practice guideline or consensus statement is developed and when
it is published or read. Guidelines and statements are not
continually updated and may not reflect the most recent evidence.
Guidelines and statements address only the topics specifically
identified therein and are not applicable to other interventions,
diseases, or stages of diseases. Furthermore, guidelines and
statements cannot account for individual variation among patients
and cannot be considered inclusive of all proper methods of care or
exclusive of other treatments. It is the responsibility of the treating
physician, relying on independent experience and knowledge, to
determine the best course of treatment for the patient. Accordingly,
adherence to any practice guideline or consensus statement is
voluntary, with the ultimate determination regarding its application
to be made by the physician in light of each patient’s individual
circumstances and preferences. CAP makes no warranty, express or
implied, regarding guidelines and statements and specifically
excludes any warranties of merchantability and fitness for a
particular use or purpose. CAP assumes no responsibility for any
injury or damage to persons or property arising out of or related to
any use of this statement or for any errors or omissions.
Guideline and Conflicts of Interest
The Update Committee was assembled in accordance with CAP
and ASCO Conflicts of Interest Management Procedures for
Clinical Practice Guidelines (ASCO procedures are summarized
at http://www.asco.org/guidelinescoi). Members of the Update
Committee completed the ASCO disclosure form, which requires
disclosure of financial and other interests that are relevant to the
subject matter of the guideline, including relationships with
commercial entities that are reasonably likely to experience direct
regulatory or commercial impact as the result of promulgation of
the guideline. Categories for disclosure include employment
relationships, consulting arrangements, stock ownership, honorar-
ia, research funding, and expert testimony. In accordance with the
procedures, the majority of the members of the Update Committee
did not disclose any such relationships.
RECOMMENDATIONS
CLINICAL QUESTION 1
What is the optimal testing algorithm for the assessment
of HER2 status?
Literature Update and Discussion
The Update Committee found more than 70 new
publications that informed a revision of the testing algorithms
contained in the original 2007 guideline. At the time of the
original guideline, significant concern existed about false-
positive HER2 test results. Guideline recommendations
emphasized those changes that would mitigate false posi-
tives, particularly relating to issues of specimen fixation and
pathologist interpretation.39,43–47 Preliminary data from an
ongoing prospective study seem to suggest that the frequency
of false-positive test results may have diminished, in that the
concordance between local testing in laboratories throughout
the United States and confirmatory central HER2 testing at
the Mayo Clinic (Rochester, MN) for the ALTTO (Adjuvant
Lapatinib and/or Trastuzumab Treatment Optimization
HER2 Adjuvant Trial) trial showed that less than 6% of
patients initially considered eligible were not subsequently
centrally confirmed as being HER2 positive.48
On the other end of the spectrum, clinical experience and
recent literature have indicated that false-negative HER2 test
results must also be considered. The Update Committee was
sensitive to the concerns that surfaced after the publication of
the 2007 guideline about the very small number of patients
potentially affected by the recommendation to consider as
HER2 positive only those tumors with more than 30% of
cells (or .10% to 30% if HER2 amplified by FISH) with
diffuse and intense circumferential staining.49 Therefore, the
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Update Committee decided to revert to the previously used
IHC criterion of more than 10% cells staining for HER2,
which had been used as an entry criterion for eligibility for
the first generation of prospective randomized trials of
adjuvant trastuzumab.18,22,49–53 The rationale for this recom-
mendation by the Update Committee is detailed in Data
Supplement 1. Aside from the very small number of patients
affected (as few as 0.15% of all newly diagnosed patients, as
previously discussed),5 the Update Committee was also of
the opinion that improvements in analytic performance of
HER2 testing in clinical practice since 2007 have further
reduced the already small number of patients potentially at
risk of receiving a false-negative test result.
Testing is now recommended for primary, recurrent, and
metastatic tumors.19,35,45,54–63,64 Tissue from the primary
tumor can be obtained through a core needle biopsy, as
well as from an incisional and excisional surgical proce-
dure.65 Metastases can be biopsied from chest wall, regional
lymph nodes, or distant organs.66–74 It is essential to ensure
that time to fixation (cold ischemic time) and time in fixative
(which has increased from 6 to 48 hours to 6 to 72 hours in
this update on the basis of available data and to conform
with the ASCO/CAP estrogen receptor [ER]/progesterone
receptor [PgR] testing guideline75,76) are recorded and
considered in defining the test result. More detail about
preanalytic issues is available in Data Supplement 6.
In summary, if available, perform the first test in the core
biopsy specimen in a patient with newly diagnosed breast
cancer. If the test result is clearly positive or clearly negative
as defined in Table 1, no retesting is needed. If the test is
negative and there is apparent histopathologic discordance
(Table 2), or if specimen handling has not been in
accordance with guideline recommendations, a section of
the tumor from the excisional specimen should be tested. If
this result is positive, no further testing is needed. However,
if the test is negative and there remains significant clinical
concern about the result after consultation between the
pathologist and the medical oncologist, it may be appro-
priate to repeat the test in a different block from the
patient’s tumor. If all three tests are negative, no additional
testing is recommended.
Data Supplement 7 is a table of IHC Interpretation
Criteria, and Data Supplement 8 provides ISH Interpretation
Criteria. Both of these Data Supplements expand on details
provided in Table 1.
The Update Committee clarified several issues in the
update on the basis of recently published literature. The
recommendations in Table 1 reflect the Update Commit-
tee’s interpretation of the new data on polysomy,
heterogeneity in ISH, types of assays, and methods of
analysis 10–14,19–21,45,67,69,79–135 for inclusion in this update.
See Data Supplement 2 for an extensive discussion of these
issues.
A list of US Food and Drug Administration (FDA) approved
assays is available at http://www.accessdata.fda.gov/scripts/
cdrh/devicesatfda/index.cfm?start_search¼1&search_term¼
HER2&approval_date_from¼&approval_date_to¼07/14/
2013&sort¼approvaldatedesc&pagenum¼10 (last checked
July 14, 2013). The product package inserts for trastuzumab
and pertuzumab prepared by the FDA indicate that ‘‘HER2
testing should be performed using US Food and Drug
Administration-approved tests by laboratories with demon-
strated proficiency.’’77,78
HER2 Assay Exclusions
Each assay type has diagnostic pitfalls to be avoided. The
Update Committee agreed that there were situations in
which one assay type was preferred because of assay or
sample considerations. Exclusion criteria to perform or
interpret an IHC or any ISH assay for HER2 are unchanged
but can be viewed in the original guideline.1,2 The
pathologist who reviews the histologic findings should
determine the optimal assay (IHC or ISH) for determination
of HER2 status.
Algorithms for HER2 Testing by IHC and ISH
Algorithms for evaluation of HER2 protein expression by
IHC and HER2 amplification by single-probe or dual-probe
ISH are presented in Figures 1, 2, and 3.
CLINICAL QUESTION 2
What strategies can help ensure optimal performance,
interpretation, and reporting of established assays?
Literature Update and Discussion
Testing analytic validation requirements.—The Update
Committee reviewed new papers and reports on strategies
to ensure optimal performance, interpretation, and report-
ing of assays.16,22,100,136,137 Most new HER2 assays have been
submitted to the FDA for premarket approval review as class
III devices in view of their use for therapy selection.
Although a new HER2 assay ideally should have its clinical
utility validated using specimens from prospective thera-
peutic trials that tested the effects of anti-HER2 therapy, the
Update Committee recognizes that the rarity of these
valuable specimens requires that new HER2 assays be
approved on the basis of concordance studies comparing
them with other established HER2 tests. Consequently, it is
important that tissues selected for such concordance studies
come from datasets that include a broad representation of
patients with breast cancer in whom HER2-positive status
will be observed in approximately 15% to 20%.
Ongoing competency assessment.—The Update Com-
mittee urges ongoing competency assessment as a part of
every laboratory’s internal quality assessment program. The
competency of the laboratory professionals and pathologists
interpreting assays must be continuously addressed as
required under the Clinical Laboratory Improvements
Amendments (CLIA 88). The acceptable performance
standard for such competency tests remains the same as
in the original guideline.
Reporting requirements.—Data Supplements 9 and 10
are tables of reporting elements for IHC and reporting
elements for ISH, respectively. Some changes have been
made to the reporting elements for IHC and ISH to ensure
that they are in accordance with the revised recommenda-
tions. In addition, a disclaimer statement is required if the
specimen handling requirements are not met.
New interpretation requirements relate to the definition of
tumor samples with genomic heterogeneity as well as the
examination of specimens and interpretation of results in
these samples. No specific requirements were added for
designation of polysomy by ISH. Laboratories should
maintain documentation of their quality assurance practices
and ensure that such documentation is available for
inspection.
Regulatory framework.—The regulatory framework
remains the same as discussed in the original guideline.
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At the current time, the FDA exercises enforcement
discretion over laboratory-developed tests (LDTs) that are
generated and performed within an individual laboratory
under CLIA 88. CLIA 88 provides stringent quality
standards for highly complex tests, which include all
predictive cancer factor assays. This legislation also requires
biannual surveys of laboratories that perform highly
complex tests, with defined criteria and actions required
when performance is deficient. However, CLIA certification
does not require that the tests performed have been shown
with a high level of evidence to have clinical utility.138,139
Moreover, FDA approval of devices, which includes in vitro
diagnostic tests such as those discussed in this guideline,
does not necessarily require demonstration that use of the
assay results in improved clinical outcomes compared with
not using the assay. The Update Committee expresses
concern about the need for greater clarity in the regulatory
environment with regard to companion diagnostic tests and
LDTs for higher-risk tumor biomarker tests, such as HER2.
Some of this has been discussed by the Evaluation of
Genomic Applications in Practice and Prevention (EGAPP)
Initiative and endorsed by the Institute of Medicine
Committee in regard to omics-based tests, as well as
others,139 and the Update Committee understands the FDA
is developing a risk-based framework to address concerns
about test accuracy and clinical utility.
Table 2. Histopathologic Features Suggestive of Possible HER2 Test Discordance
Criteria to Consider*
New HER2 test should not be ordered if the following histopathologic findings occur and the initial HER2 test was negative:
Histologic grade 1 carcinoma of the following types:
Infiltrating ductal or lobular carcinoma, ER and PgR positive
Tubular (at least 90% pure)
Mucinous (at least 90% pure)
Cribriform (at least 90% pure)
Adenoid cystic carcinoma (90% pure) and often triple negative
Similarly, a new HER2 test should be ordered if the following histopathologic findings occur and the initial HER2 test was positive:
Histologic grade 1 carcinoma of the following types:
Infiltrating ductal or lobular carcinoma, ER and PgR positive
Tubular (at least 90% pure)
Mucinous (at least 90% pure)
Cribriform (at least 90% pure)
Adenoid cystic carcinoma (90% pure) and often triple negative
If the initial HER2 test result in a core needle biopsy specimen of a primary breast cancer is negative, a new HER2 test must be
ordered on the excision specimen if one of the following is observed:
Tumor is grade 3
Amount of invasive tumor in the core biopsy is small
Resection specimen contains high-grade carcinoma that is morphologically distinct from that in the core
Core biopsy result is equivocal for HER2 after testing by both ISH and IHC
There is doubt about the specimen handling of the core biopsy (long ischemic time, short time in fixative, different fixative) or the
test is suspected by the pathologist to be negative on the basis of testing error
Abbreviations: ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; IHC, immunohistochemistry; ISH, in situ hybridization; PgR,
progesterone receptor.
*Criteria to consider if there are concerns regarding discordance with apparent histopathologic findings and possible false-negative or false-positive
HER2 test result.
Figure 1. Algorithm for evaluation of human
epidermal growth factor receptor 2 (HER2)
protein expression by immunohistochemistry
(IHC) assay of the invasive component of a
breast cancer specimen. Although categories
of HER2 status by IHC can be created that are
not covered by these definitions, in practice
they are rare and if encountered should be
considered IHC 2þ equivocal. ISH, in situ
hybridization. NOTE: the final reported re-
sults assume that there is no apparent
histopathologic discordance observed by the
pathologist. (*) Readily appreciated using a
low-power objective and observed within a
homogeneous and contiguous invasive cell
population.
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Optimal external quality assurance methods to ensure
accuracy in HER2 testing and laboratory accredita-
tion.—External proficiency testing is a mandatory require-
ment for CAP-accredited laboratories, beginning with the
2007 guideline. External proficiency testing challenge failure
requires investigation and corrective action before the
laboratory can continue to offer HER2 testing.
CAP modified its laboratory accreditation program to
include more careful scrutiny of HER2 testing, thus creating
a mandatory and expanded proficiency testing program to
evaluate laboratory performance. The systematic review
revealed many new papers on quality assurance, quality
improvement, proficiency testing, and establishment of
concordance between local and central laboratories, both
in the United States and internationally.40,51,136,140–146 A
revised table addressing proficiency testing is contained in
Data Supplement 11, which describes statistical require-
ments for proficiency testing. Examples of international
external quality assurance schemas are included in Data
Supplement 12.
The number of laboratories participating in predictive
marker proficiency testing for HER2 and ER as part of the
CAP laboratory improvement program since 2004 is shown
in Figure 4, and the program is described at http://www.cap.
org/apps/cap.portal?_nfpb¼true&_pageLabel¼accreditation
(last checked July 14, 2013).
Figure 2. Algorithm for evaluation of human
epidermal growth factor receptor 2 (HER2)
gene amplification by in situ hybridization
(ISH) assay of the invasive component of a
breast cancer specimen using a single-signal
(HER2 gene) assay (single-probe ISH). Am-
plification in a single-probe ISH assay is
defined by examining the average HER2 copy
number. If there is a second contiguous
population of cells with increased HER2
signals per cell, and this cell population
consists of more than 10% of tumor cells on
the slide (defined by image analysis or visual
estimation of the ISH or immunohistochemis-
try [IHC] slide), a separate counting of at least
20 nonoverlapping cells must also be per-
formed within this cell population and also
reported. Although categories of HER2 status
by ISH can be created that are not covered by
these definitions, in practice they are rare and
if encountered should be considered ISH
equivocal (see Data Supplement 2E). NOTE:
the final reported results assume that there is
no apparent histopathologic discordance ob-
served by the pathologist. (*) Observed in a
homogeneous and contiguous population.
Figure 3. Algorithm for evaluation of human
epidermal growth factor receptor 2 (HER2)
gene amplification by in situ hybridization
(ISH) assay of the invasive component of a
breast cancer specimen using a dual-signal
(HER2 gene) assay (dual-probe ISH). Ampli-
fication in a dual-probe ISH assay is defined
by examining first the HER2/CEP17 ratio
followed by the average HER2 copy number
(see Data Supplement 2E for more details). If
there is a second contiguous population of
cells with increased HER2 signals per cell, and
this cell population consists of more than
10% of tumor cells on the slide (defined by
image analysis or visual estimation of the ISH
or immunohistochemistry [IHC] slide), a
separate counting of at least 20 nonoverlap-
ping cells must also be performed within this
cell population and also reported. Although
categories of HER2 status by ISH can be
created that are not covered by these
definitions, in practice they are rare and if
encountered should be considered ISH equiv-
ocal (see Data Supplement 2E). NOTE. The
final reported results assume that there is no
apparent histopathologic discordance ob-
served by the pathologist. (*) Observed in a
homogeneous and contiguous population. (†)
See Data Supplement 2E for more information
on these rare scenarios.
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Ongoing Communication, Education,
and Evaluation Efforts by CAP
CAP has undertaken comprehensive efforts to educate
pathologists about ways to improve laboratory performance
of HER2, ER, and PgR assays. Numerous live and online
educational offerings are available from CAP and other
organizations. Examples in North America include the
American Society of Clinical Pathology (ASCP) and United
States and Canadian Academy of Pathology (USCAP). CAP
provides varied live and online education focused on HER2
and ER/PgR testing elements of relevance to pathologists in
meeting the original ASCO/CAP HER2 and ER/PgR
guidelines and updates. In follow-up surveys, participants
routinely report they made changes to their practice as a
result of the educational experience. Many of these learning
opportunities have a scored assessment component, allow-
ing participants to test their knowledge as part of
completing the courses, and can be used to meet the
American Board of Pathology (ABP), the US pathologist
certifying organization, Maintenance of Certification re-
quirements. More information can be found at the CAP
learning portal (http://www.cap.org) and in the original
guideline. CAP has also created a listing of competencies in
breast pathology, compiled by experts and available for
pathologist self-assessment. After taking this self-assess-
ment, pathologists are prompted to learning offerings that
target those areas of self-reported educational deficiency. A
listing of the courses is available online at http://www.cap.
org via the learning portal.
STUDY QUALITY, LIMITATIONS OF THE LITERATURE,
AND FUTURE RESEARCH
Whether in the context of trastuzumab clinical trials or of
studies comparing HER2 testing platforms, interpretation of
the literature in the field of HER2 testing is still complicated
by a lack of standardization across trials in assay utilization
and interpretation, presence or absence of confirmatory
testing, and local versus central laboratory testing, among
other considerations. Although FDA-approved assays have
been carefully validated, not all LDTs may have, which
complicates direct comparisons across trials and platforms,
and we maintain that this situation leaves open the
possibility that a substantial percentage of some patients
with breast cancer could be either over- or undertreated
with HER2-targeted therapies.
An important gap in the literature identified by the
Update Committee concerns those patients with test results
reported as equivocal. The decision to treat with specific
therapies like trastuzumab is by necessity dichotomous (yes
or no) and will not be informed by an equivocal diagnosis
with respect to HER2 status without repeat testing, if
possible. However, HER2 test results are derived from a
continuous variable, which can be expected to lead to some
results falling into a gray area. Adding to this confusion is
the fact that there is variability in the reporting definitions of
the equivocal ranges for both bright-field ISH and FISH
assays.
The literature is lacking evidence on response to HER2-
targeted therapy in the subgroup of patients with equivocal
results, and there are limited efficacy data in the subgroup
tested with both high quality IHC and FISH and found to
have a discordant result between these two tests. Patients
with such results constitute poorly studied subsets for which
there is less confidence in the scores and actual benefit from
trastuzumab therapy. Because the retrospective evaluation
of the benefit from trastuzumab in patients with apparent
discordance between IHC and FISH who were enrolled onto
the first generation of trastuzumab trials included only a
small number of patients in each of the discordant subsets,
patients who would have qualified for enrollment in those
trials should be considered for HER2-targeted therapy.
The Update Committee’s goal was to address the most
common clinical situations encountered by pathologists and
Figure 4. Number of laboratories participating
in predictive marker proficiency testing for
human epidermal growth factor receptor 2
(HER2) by immunohistochemistry (IHC),
HER2 by fluorescent in situ hybridization
(FISH), and estrogen receptor (ER) by IHC
through the College of American Pathologists
(CAP) Laboratory Improvement Program.
Arrows indicate the years during which the
HER2 and hormone receptor testing guide-
lines were published by the American Society
of Clinical Oncology (ASCO)/CAP. The num-
bers of participating laboratories are shown
both graphically and in tabular form. After the
publication of the 2007 ASCO/CAP HER2
and the 2010 ASCO/CAP ER/progesterone
receptor testing guidelines, there was a
significant increase in the number of labora-
tories in the United States and elsewhere
participating in CAP proficiency testing sur-
veys in breast cancer (http://www.cap.org/
apps/cap.portal?_nfpb¼true&_pageLabel
¼accreditation; last checked June 14, 2013).
CAP has a core goal to improve the quality of
pathology and laboratory services through
education and standard setting in order to
enhance patient safety, and help laboratories
meet or exceed regulatory requirements set
by the Centers for Medicare and Medicaid
Services, the Joint Commission, and many
states in the United States.
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oncologists in routine clinical practice. Specifically in regard
to ISH assays, it expected that additional but rare categories
of HER2 status by ISH could be created that are not covered
by the definitions illustrated in Figures 2 and 3. Data
Supplement 2E addresses a narrower set of scenarios that
may on occasion be observed with dual-signal ISH assays.
For patients with low levels of HER2 expression that do
not reach the threshold for HER2-positive disease, the
Update Committee encourages enrollment of such patients,
if eligible, onto prospective clinical trials that aim to address
the value of adjuvant HER2-targeted therapies in patients
whose breast cancers show low levels of HER2 expression,
like the NSABP B-47 (National Surgical Adjuvant Breast and
Bowel Project B-47) trial (NCT01275677). The Update
Committee also supports participation in studies evaluating
other cutoffs and other technologies to optimize eligibility
for HER2-targeted therapies.
PATIENT AND CLINICIAN COMMUNICATION
Patients (and family members or caregivers) should be
educated about the results of pathology tests and how they
are used to develop a treatment plan tailored to the biology
of their cancers. Because many newly diagnosed patients are
under emotional stress and/or may be unaccustomed to
complex medical terminology, the use of easily understood
language (at an educational level that the patient can
understand) is key to clear communication. Asking patients
to repeat back key pieces of information, providing written
or recorded notes, and using visual aids can help ensure
information is effectively communicated.
Patients should be given a copy of their pathology report
and HER2 test results. The clinician should review the
results with the patient, discuss any issues with the test
interpretation or performance, and ask if he or she has any
additional questions about the results.
Key Points for Clinicians to Discuss With Patients
Regarding HER2 Status
Explain the importance of determining the biologic
characteristics of breast cancer.—Patients should under-
stand that the most common biologic tests are those for ER,
PgR, and HER2 and that testing for these markers is
important to select an appropriate treatment. The overall
percentage of patients with HER2-positive breast cancer is
between 15% and 20%. Observed numbers may vary
depending on the population being tested by individual
laboratories.
Explain the importance of HER2 testing.—Patients
should understand that HER2 status determines whether
certain drugs (eg, trastuzumab, lapatinib, pertuzumab, T-
DM1) are recommended. They should also understand that
the HER2 gene is important in tumor cell growth and that
tumors that have increased levels of HER2 (as measured by
HER2 gene amplification or HER2 protein overexpression)
usually have a higher growth rate and a more aggressive
clinical behavior.
Explain the type of tissue used for HER2 testing.—
Patients should understand the type of tissue used for HER2
testing (eg, core biopsy, excisional biopsy).
Explain the types of tests used to determine HER2
status.—Patients should understand that there are differ-
ent FDA-approved testing methods that detect HER2
protein overexpression or the presence of HER2 gene
amplification.
Explain the interpretation of the HER2 test results.—
Patients should understand that although most HER2 test
results are definitively positive or negative, there are
equivocal results that require additional testing using an
alternative test or using the same or alternative test on a
different portion of the same specimen (different block).
Sometimes, the oncologist or pathologist may recommend
additional testing using a different type of tumor specimen
(eg, surgical excision v core biopsy), if available. Patients
should be informed about which test or tests were
performed and the expected turnaround time for these
tests. Unfortunately, some results remain indeterminate or
inconsistent with other histopathologic findings. In such
cases, a final treatment decision to consider treatment with
HER2-targeted therapy should be made after consultation
between the pathologist and oncologist and a discussion
with the patient.
Explain the importance of retesting HER2 status in
new, metastatic tumors.—Patients should understand that
HER2 status may occasionally be different (discordant)
when comparing a previous primary tumor and a site of
recurrence or in the setting of multiple simultaneous
metastatic sites. In some cases, it is not possible to fully
differentiate between a true biologic change, tumor hetero-
geneity, or variability in the performance of the assay.
Explain that HER2 testing guidelines exist.—Patients
should be assured that HER2 testing guidelines were
followed. Refer patients to the ASCO/CAP guideline update
at www.asco.org/guideline/her2 and/or http://www.cap.org
and to www.cancer.net for additional patient-focused
information.
HEALTH DISPARITIES
Although ASCO clinical practice guidelines present
recommendations on the best practices in diagnosis and
disease management to provide the highest level of cancer
diagnosis and care, it is important to note that some racial/
ethnic minority patients have limited access to optimal
medical care and/or accredited pathology laboratories. At
the same time, some Medicaid or uninsured patients may
have access to accredited pathology laboratories by virtue of
receiving some or all of their care in an academic medical
center.147–150
Disparities clearly exist in the likelihood of receiving HER2
testing. In the United States, Lund et al151 used data from
the National Cancer Institute Metropolitan Atlanta SEER
Registry in conjunction with the Georgia Comprehensive
Cancer Registry to examine HER2 testing among all cases of
primary invasive breast cancer diagnosed among female
residents during 2003 to 2004. Overall, 90.1% of women had
evidence of HER2 testing. Rates of HER2 testing did not
vary significantly based on socioeconomic status (based on
the percent living below the federal poverty level) and were
similar between black (91.3%) and white (89.8%) women.
This is in agreement with other reports showing similar or
greater rates of HER2 testing among black versus white
women with breast cancer.152 However, in the Lund et al
study, Hispanic women were significantly less likely to
receive HER2 testing (79.3%), as were women diagnosed
with stage IV (80.7%) or unknown stage (71.7%) disease. In
addition, the mean age of women who received HER2
testing (58.8 years) was significantly younger than that of
women who did not receive testing (61.3 years). Other
studies have also reported that older women153,154 and those
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with distant disease are significantly less likely to have
documentation of HER2 testing. Stark et al155 also reported
that women with capitated insurance (versus fee-for-service
insurance) were significantly more likely to be tested for
HER2 status. Awareness of possible disparities in access to
care should be considered in the context of this clinical
practice guideline, and health care providers should strive to
deliver the highest level of cancer care to these vulnerable
populations.
ADDITIONAL RESOURCES
Data Supplements, including evidence tables, and clinical
tools and resources can be found at www.asco.org/
guidelines/her2. Information for patients is available at
http://www.cancer.net.
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